Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.
about
Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studiesNonproliferative and Proliferative Lesions of the Rat and Mouse Skeletal Tissues (Bones, Joints, and Teeth)Etiology and pathogenesis of osteochondrosisMicroarray analysis of irradiated growth plate zones following laser microdissection shows later importance of differentially expressed genes during radiorecovery.Anti-VEGF Cancer Therapy in Nephrology PracticePhase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamicsMagnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials.The VEGF pathway in cancer and disease: responses, resistance, and the path forward.Clinical review: kinase inhibitors: adverse effects related to the endocrine system.Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.Safety assessment considerations and strategies for targeted small molecule cancer therapeutics in drug discovery.Head and neck lymphatic tumors and bony abnormalities: a clinical and molecular reviewMesenchymal stem cells and alginate microcarriers for craniofacial bone tissue engineering: A review.Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.Preclinical evaluation of the novel multi-targeted agent R1530.Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model.Regenerative Medicine Approaches for the Treatment of Pediatric Physeal Injuries.Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway.Incisor degeneration in rats induced by vascular endothelial growth factor/fibroblast growth factor receptor tyrosine kinase inhibition.Femoral Head Growth Plate Dysplasia and Fracture in Juvenile Rabbits Induced by Off-target Antiangiogenic Treatment.Drug-induced Physeal Abnormalities in Preclinical Toxicity Studies.PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary.Preclinical toxicity of AZD7969: Effects of GSK3β inhibition in adult stem cells.
P2860
Q26781698-8849919D-C718-4A63-A7A2-0342E3A53675Q28079465-BADC36B7-E560-47FE-9F3A-7C9237FCAD94Q28235075-7EE893CD-567E-451B-952D-3A2601CC7DC9Q33628590-DBEDDE09-E223-45D7-BA63-7923A7E956F3Q34152125-A8F92338-D720-42BD-8948-22A97ADD0344Q34488803-8A615A1C-695D-4103-A812-6479592B2A0AQ34543413-8B720367-9480-4211-8E70-F5761BCC3FB5Q35003666-F6CF21AB-0C43-4560-BCF7-D7B494D4CC1DQ35021664-755D14E4-FB2A-43BF-8866-60A8E487F2B8Q35599819-F8D9396B-762C-4990-ADE0-36FEA43FD65DQ36226051-245561B9-95CC-4E9B-B3E1-D65F021CDC75Q36526512-F06DAD41-CFEA-49C1-AE50-2358921FF3ADQ36736494-9A452146-682D-45DE-9BC7-4775EB847A6AQ37401839-FED50230-6453-4AB8-9F61-7C2495CE0464Q37492128-100AFB7C-365C-4BB3-BB80-5E5EEA193B10Q37631309-71C37FCE-7ECB-4C0D-94C9-DC5A5F2F1189Q37971104-8EBD60C2-C3E4-4D31-860E-73CD047FDFF7Q38716473-E0E02824-5A58-4FE0-8C9B-5D53EB9AC9E4Q39204706-CD88FC12-10AF-4D46-A2E2-A7BE1BB6F4F4Q39546167-45A53115-AC94-4393-96EA-099BA7F84199Q39555847-F09FCC58-56EB-4169-9D2E-9C0CCBBF5431Q39584429-9219D06F-4C92-46CD-905B-F7E1D3489F4FQ40084134-73E9947F-2AF7-4807-B1BA-95B232CE18BFQ42106848-03DB764A-4256-49F5-B299-1B08AA7BD16FQ43184381-67196C52-3927-476F-874B-86819F137D40Q46550877-E6B40569-B803-4990-AA53-DAC86492A79FQ50927781-C4FEEDE3-F2AD-433F-A4C8-CB00108C00D3Q53187474-63EAF5A2-FF44-4BA3-B3F9-3C0E4A2755B0Q54314798-B01D38E0-DCC2-453A-8E78-2702D905B9B0
P2860
Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.
@ast
Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.
@en
type
label
Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.
@ast
Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.
@en
prefLabel
Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.
@ast
Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.
@en
P2093
P2860
P1476
Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.
@en
P2093
Anthony P Hall
F Russell Westwood
Peter F Wadsworth
P2860
P304
P356
10.1080/01926230600611836
P407
P577
2006-01-01T00:00:00Z